Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,230.12
(
0.29%
)
US TECH 100
26,942.00
(
0.87%
)
Dow Jones
49,499.27
(
-0.31%
)
Brent Oil
107.80
(
0.00%
)
Bitcoin
78,767.99
(
0.73%
)
News Focus
News Focus
Post# of 257484
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122926
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 242313

Thursday, 07/28/2022 9:23:38 AM

Thursday, July 28, 2022 9:23:38 AM

Post# of 257484
PFE 2Q22 results—2022 guidance for Comirnaty and Paxlovid remain $32B and $22B, respectively:

https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-second-quarter-2022-results

2022 non-GAAP EPS guidance is now $6.30-6.45 (from the prior range of $6.25-6.45), despite an increased headwind of $0.24/sh from currency exchange rates (i.e. the strong US dollar).


CC slides:
https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Charts-FINAL.pdf

Transcript of CC prepared remarks:
https://s28.q4cdn.com/781576035/files/doc_financials/2022/q2/Q2-2022-Earnings-Conference-Call-Prepared-Remarks-FINAL.pdf

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today